BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32717621)

  • 1. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
    Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
    Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
    Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
    Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
    Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
    Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
    Jaehne M; Roeser K; Jaekel T; Schepers JD; Albert N; Löning T
    Cancer; 2005 Jun; 103(12):2526-33. PubMed ID: 15900577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
    Yang RK; Zhao P; Lu C; Luo J; Hu R
    Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
    Sousa LG; Wang K; Torman D; Binks BJ; Rubin ML; Andersen CR; Lewis WE; Rivera MJ; Kaya D; El-Naggar AK; Hanna EY; Esmaeli B; Frank SJ; Bell D; Glisson BS; Rodon J; Meric-Bernstam F; Lee JJ; Ferrarotto R
    Cancer; 2022 Feb; 128(3):509-518. PubMed ID: 34661906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
    Jeong ISD; Moyers J; Thung I; Thinn MM
    Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
    Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K
    Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM; Chiosea SI
    Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
    Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE
    Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone in metastatic salivary duct carcinoma.
    Urban D; Rischin D; Angel C; D'Costa I; Solomon B
    J Natl Compr Canc Netw; 2015 Mar; 13(3):288-90. PubMed ID: 25736005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
    van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
    Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract.
    Agaimy A; Mueller SK; Bishop JA; Chiosea SI
    Head Neck Pathol; 2021 Sep; 15(3):769-779. PubMed ID: 33428064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of HER2-targeted therapy on PDX and PDX-derived organoids generated from HER2-positive salivary duct carcinoma.
    Aoyama J; Nojima Y; Sano D; Hirai Y; Kijima N; Aizawa Y; Takada K; Hatano T; Takahashi H; Nishimura G; Oridate N
    Head Neck; 2023 Jul; 45(7):1801-1811. PubMed ID: 37184432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
    Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
    Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and outcome analysis of salivary duct carcinoma.
    Han MW; Roh JL; Choi SH; Nam SY; Lee HJ; Cho KJ; Lee SW; Kim SY
    Auris Nasus Larynx; 2015 Dec; 42(6):472-7. PubMed ID: 26028371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
    Taha T; Billan S
    Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.